Bionano Genomics Inc
BNGO
Get informed when a big investor buys or sells
+ FollowMarket Cap$14M
Close$
$1.11
16.6% downside
Current Fair Value
16.6% downsideOvervalued by 16.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.00 Million |
|---|---|
| Enterprise Value | $18.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.85 |
| Beta | 1.65 |
| Outstanding Shares | 11,546,000 |
Return
| Return on Equity | -101.76% |
|---|---|
| Return on Assets | -67.58% |
| Return on Invested Capital | -110.10% |
Valuation & Multiples
| P/E Ratio | -0.33 |
|---|---|
| PEG | -3.96 |
| Price to Sales | 0.67 |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | 0.6 |
| Enterprise Value to EBIT | -0.44 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.70
Average shareholder expectationRevenue Estimate
$7.55 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$8.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.14%▼ 1.79% |
|---|---|
| Total Invested | $801,579▼ 21.27% |
| Investors Holding | 33▲ 2.00% |
ESG Score
No data
About Bionano Genomics Inc
147 employees
CEO: R. Erik Holmlin